Supergut, a prebiotic nutrition startup, plans to raise a Series B within the next three to six months, CEO Marc Washington tells Axios exclusively.
Why it matters: The company is capitalizing on demand for prebiotic fiber products, which it says boosts insulin production hormone GLP-1 — the same one harnessed by obesity and weight loss drugs like Ozempic and Wegovy.
